Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
Sundar Jagannath(Mount Sinai Hospital), Carolyn C. Jackson(Centro de Investigación del Cáncer), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), Mounzer Agha(Dana-Farber Cancer Institute), Adam D. Cohen(Penn Center for AIDS Research), Parameswaran Hari(Medical College of Wisconsin), Jesús G. Berdeja(Tennessee Oncology), Marlene J. Carrasco-Alfonso, Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Thomas G. Martin(University of California San Francisco Medical Center), William Deraedt(Janssen (Belgium)), Muhammad Akram(Unknown), Yi Lin, Xiaoling Wu(South China University of Technology), Alicia J. Allred(Queen's University Belfast), Tzu‐Min Yeh(Centro de Investigación del Cáncer)
Cited by 37
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Awareness and current knowledge of breast cancer
|Biological Research|2017|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k